Pharmaceuticals
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
3041
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
1002
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
* The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an important milestone in its global clinical dev...
2025-11-21 12:01
1034
HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
* Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH...
2025-11-20 22:30
892
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
* The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. * The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 cli...
2025-11-20 18:52
1227
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological
advancement, further strengthening its ability to support innovators worldwide
as they deliver breakthrough medicines for patients.
SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan
2025-11-20 10:00
745
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] wo...
2025-11-20 03:00
1131
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe
2025, one of the industry's premier gatherings for innovation in protein and
antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein
2025-11-19 22:17
896
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...
2025-11-19 20:08
651
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...
2025-11-19 08:00
962
Kangpu to Present Latest Study Results of epaldeudomide (KPG-818) at the 67th ASH Annual Meeting
HEFEI, China, Nov. 18, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I clinical trial results of epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hema...
2025-11-18 21:00
811
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract de...
2025-11-17 22:26
975
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection...
2025-11-17 22:06
1205
Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to initiat...
2025-11-17 10:29
1199
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
* Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients acrossJapan * Similar marketing authorization...
2025-11-14 17:43
810
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka; President and COO:Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirm...
2025-11-14 16:00
861
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 14, 2025 /PRNewswire/ -- On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong's first Chinese-language financial newspaper, hosted the "ESG & Sustainability Awards of Excellence 2025" ceremony. At the event, Fosun International received the "ESG & Corporate Sustainab...
2025-11-14 09:00
2434
Herbalgy Unveils a New Campaign Featuring Cecilia Yeung in Conversation with Professor Wong Tin Chee Introducing Touch-Cool 5 ml Portable Edition and the New Herbalgy Analgesic Plaster
HONG KONG, Nov. 14, 2025 /PRNewswire/ -- Herbalgy, Hong Kong's trusted pain management specialist, today unveils an inspiring new brand campaign that marks a significant milestone in the company's evolution. The campaign features an authentic conversation betweenHong Kong's record-breaking high j...
2025-11-14 09:00
882
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blo...
2025-11-13 21:00
866
HKSH Medical Group Hosts Hong Kong's First Asia-Oceania Particle Therapy Co-operative Group Conference
Uniting Global Proton Therapy Leaders to Advance Precision Cancer Treatment HONG KONG, Nov. 13, 2025 /PRNewswire/ -- Hosted by The Li Shu Fan Medical Foundation and HKSH Medical Group (HKSH), and organised by the Asia-Oceania Particle Therapy Co-operative Group (PTCOG-AO), the 5th Annual Conferen...
2025-11-13 19:22
1010
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4894
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3985
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3893
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3390
Cyient Semiconductors Qualifies for Key Bid in Semi-Conductor Laboratory-Mohali Revamp
2025-12-06 02:00
2660